Compugen Ltd.
72 Pinchas Rosen Street
Tel Aviv
69512
Tel: 972-3-765-8585
Fax: 972-3-765-8555
Website: http://www.cgen.com/
Email: info@cgen.com
411 articles with Compugen Ltd.
-
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
3/15/2023
Compugen Ltd. today announced that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) annual meeting on April 14-19, 2023, in Orlando, Florida.
-
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
3/8/2023
Compugen Ltd. today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference (virtual), on Wednesday, March 15, 2023 at 10:00 AM ET .
-
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study
3/6/2023
Compugen Ltd. today announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701.
-
Compugen Reports Fourth Quarter and Full Year 2022 Results
2/27/2023
Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2022 and provided an update on its main highlights from 2022 and future plans.
-
Compugen to Present at the SVB Securities Global Biopharma Conference
2/9/2023
Compugen Ltd. today announced that management will present at the SVB Securities Global Biopharma Conference (virtual), on Thursday, February 16, 2023 at 9:20 AM ET.
-
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
1/23/2023
Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen's leadership in the DNAM-1 axis.
-
The past decade has seen an immuno-oncology revolution, but there is still work to be done. BioSpace looks at innovative research from Nectin Therapeutics, Compugen and Biond Biologics.
-
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer
12/6/2022
Compugen Ltd. announced today publication of ePosters by ESMO Immuno-Oncology Congress 2022 (ESMO-IO), showing that Compugen's COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 (anti-TIGIT) demonstrated preliminary durable anti-tumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile.
-
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients
12/1/2022
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today publication of abstracts by ESMO-IO showing that at the time of abstract data cutoff, Compugen's COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 demonstrated preliminary anti-tumor activity and immune activation in platinum resistant ovarian cancer patients and was well tolerated.
-
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
11/29/2022
Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities Hematology and Oncology Summit. The fireside chat will take place on Tuesday, December 6, 2022, at 10:20 am ET.
-
AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.
-
Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific
11/16/2022
Compugen Ltd. announced today that it expects to receive a milestone payment of $7.5 million from AstraZeneca, after AstraZeneca dosed the first patient in its ARTEMIDE Phase 2 study with AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, Compugen's clinical-stage anti-TIGIT antibody.
-
Compugen Reports Third Quarter 2022 Results
11/14/2022
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and announced financial results for the third quarter ended September 30, 2022.
-
Compugen to Participate in the Stifel Healthcare Conference
11/8/2022
Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a fireside chat at the upcoming Stifel 2022 Healthcare Conference in New York City.
-
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients
11/7/2022
Compugen Ltd. announced publication of the abstract on data demonstrating that anti-tumor activity following blockade of PVRIG with COM701 is supported by potent tumor microenvironment immune activation in MSS-CRC patients.
-
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients
11/7/2022
Compugen Ltd. announced publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients.
-
Compugen Announces Receipt of Nasdaq Delisting Notice
11/2/2022
Compugen Ltd. announced today that on October 31, 2022 , it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").
-
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
10/31/2022
Compugen Ltd. announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.
-
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.
-
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
10/6/2022
Compugen Ltd. announced today that it will present new clinical data from its dual combination COM701/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston, MA.